Published July 23, 2026
Nearly a year after the FDA moved to change how acetaminophen is labeled during pregnancy, the warning families expected still hasn't materialized. On September 22, 2025, the agency announced it was initiating a label change and sent a letter to physicians nationwide, citing multiple studies suggesting a correlation between prenatal acetaminophen use and later autism or ADHD diagnoses in children. The FDA was explicit that the studies show an association, not proof of causation, and it stressed that acetaminophen remains the safest over-the-counter option for treating pain and fever during pregnancy compared to the alternatives.
Kenvue, the company that makes Tylenol, pushed back immediately, stating it continues to believe no causal link between acetaminophen and autism has been established and noting that regulators and medical groups had previously affirmed the drug's safety profile. That back-and-forth set up a slow-moving standoff between the FDA's stated intent and the company that controls the actual label text.
Kenvue updated Tylenol's packaging on May 27, 2026 — the company's most recent labeling change since the FDA's September 2025 announcement. According to legal industry tracking of the litigation, that update did not add any autism or ADHD warning language. The label continues to instruct pregnant and breastfeeding users to consult a health professional before use, the same general guidance that predates the FDA's announcement. The FDA has not issued a further public update on its label-change plans since.
That gap between regulatory intent and the product actually on store shelves has become a talking point in the ongoing litigation. Plaintiffs' attorneys have pointed to the FDA's own findings as support for their case, while Kenvue continues to argue the underlying science doesn't support a warning at all — a dispute now playing out in parallel with the revived federal court cases.
The absence of a label warning doesn't affect whether a family can pursue a claim over a child's autism or ADHD diagnosis linked to prenatal Tylenol use — those cases proceed based on medical and scientific evidence, not the label itself. See Atumio's Tylenol autism lawsuit page for a free eligibility review, or start your case review directly.